Malabsorption Syndrome Market Analysis

Malabsorption Syndrome Market Overview

The malabsorption syndrome market is expected to reach USD 3,771.16 Million by 2030 at 6.2% CAGR during the forecast period 2022-2030. Unmet medical demands, growing government support, rising healthcare spending in developed nations, improved regulatory framework, increasing adoption rate, and rising financing and reimbursement policies are all contributing to the malabsorption syndrome market growth.

Malabsorption syndrome is characterized by insufficient absorption of lipids, vitamins, carbohydrates, protein, and other nutrients from the intestine into the circulation. Prolonged antibiotic usage, Celiac disease, cystic fibrosis, Crohn's disease, lactose intolerance, parasite illnesses, gallbladder or liver disease, and intestinal inflammation are all potential causes of malabsorption syndrome.

Growing incidences of cause disorders like celiac disease and others are cited as a major reason fueling the malabsorption syndrome industry. According to the Celiac Disease Foundation, celiac disease is a dangerous autoimmune illness that affects one in every 100 persons globally.

Covid-19 Analysis

With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. Pharmaceutical and biotech businesses, along with governments across the globe, are collaborating to handle the Covid-19 epidemic, from vaccine research to planning for pharmaceutical supply chain issues.

Approximately 115 vaccine candidates and 155 compounds are now in the R&D pathway. Furthermore, routinely used medications such as hydroxychloroquine have shown a huge increase in demand for Covid-19 control. Because of the enormous demand for these treatments, makers of Covid-19 management pharmaceuticals have a lot of chances, since many wealthy nations are running out of them. As a result of the demand for Covid-19 vaccines and treatment medications, the pharmaceutical & biotechnology sectors are predicted to increase significantly in the future. This, in turn, is likely to have a major influence on the global market for malabsorption syndrome.

Market Dynamics

Drivers

The increasing number of cases of causative diseases like celiac disease and others are expected to fuel the growth of the malabsorption syndrome market share. Increased prevalence of digestive diseases and associated illnesses will drive the market expansion. Likewise, the increased financial support rendered for researchers to explore innovative interventions and an increased rate of certain cancers where radiation therapy is used as the primary treatment will propel the market growth.

Opportunities

Growing healthcare costs in developed nations, as well as an enhanced regulatory environment, are likely to create more potential for the malabsorption syndrome market value to rise. Moreover, the key players of the market are adopting various R&D initiatives and industry trends such as product launches to fuel market expansion.

Restraints

Some factors are predicted to hinder the market share expansion. The absence of a healthcare budget in several middle-income countries, a shortage of trained workforce and severe safety standards, and the failures of clinical trials during the development phase are among the primary issues limiting the market growth.

Challenges

The absence of healthcare resources in some low-income countries, an inadequately trained staff, and strict safety regulations may act as factors that slow down the market growth. This will further challenge the malabsorption syndrome market over the forecast years.

Cumulative Growth Analysis

The malabsorption syndrome market is anticipated to grow substantially in the years to come. The pharmacy computerization systems market value is expected to grow at a CAGR of about 11%. Unmet medical demands, growing government support, rising healthcare spending in developed nations, improved regulatory framework, increasing adoption rate, and rising financing and reimbursement policies are all contributing to the malabsorption syndrome market growth.

Value Chain Analysis

Malabsorption syndrome refers to a group of digestive illnesses where the small intestine is unable to absorb nutrients, vitamins, or minerals from the digestive system into circulation. Malabsorption syndrome has also been linked to several illnesses, including digestive issues, chronic antibiotic usage, and surgery. It can also be caused by a lack of digestive enzyme synthesis. People suffering from malabsorption experience fatigue, weight loss, or gastrointestinal discomfort.

A rise in the number of gastrointestinal issues and other diseases will boost malabsorption syndrome market growth. Moreover, large financial assistance to researchers for creating newer interventions, and an increase in the incidence of certain cancers where radiation therapy is used as the primary treatment are some of the key factors driving the growth of the market value. Also, the increase in market investments in R&D, as well as partnerships for product development, would provide new possibilities for during the market forecast.

Segment Overview

The global malabsorption syndrome market is classified into many segments, such as causative diseases, diagnosis, treatment, and end-user. Listed below are the malabsorption disorder market segments:

By causative diseases

• Cystic fibrosis


• Parasitic diseases


• Intestinal disorders




• Celiac disease


• Others




• Lactose intolerance


• Whipple’s disease


• Tropical sprue


• Others

By diagnosis

• Imaging studies




• Ct scan


• Endoscopic retrograde cholangiopancreatogram (ERCP)


• Magnetic resonance cholangiopancreatography (MRCP)


• Abdominal x-ray




• Hematologic tests


• Other tests




• Test of fat malabsorption


• Tests of carbohydrate absorption


• Schilling test


• D-xylose test


• Test of bile salt absorption


• C-d-xylose breath test

By treatment 

• Gluten-free diet


• Anti-inflammatory drugs


• Antibiotics


• Nutritional supplements


• Protease and lipase supplements


• Antidiarrheal agents


• Others

By end-user

• Hospitals


• Academic and Research Institutes


• Pharmaceutical companies


• Nutrition Clinics


• Others

Regional Analysis

The malabsorption syndrome market analysis division comprises North America, Europe, Asia Pacific, and the rest of the world. Because of increased rates of causative disorders such as lactose intolerance, cystic fibrosis, diarrhea, and others, along with high health expenditures, the Americas lead the market. Adults and children suffering from cystic fibrosis are at risk of developing decreased bone density and accompanying problems owing to nutritional loss. 

Europe is the second-largest market for malabsorption syndrome. The government's support towards research and development, and its attempts to enhance reimbursement systems in healthcare are also projected to boost the European market. Due to a large patient population and improving healthcare technologies, estimated To be the fastest growing market. Healthcare spending is also rising in many Asia Pacific countries. As per the Australian Institute of Health and Welfare, overall health spending in Australia in 2015 was around USD 170.4 billion. Due to inadequate technical expertise and inadequate medical facilities, the Middle East and Africa have the smallest proportion of the Malabsorption Syndrome Market.

Competitive Landscape

The malabsorption syndrome industry is dominated by a few companies that play a vital role in the market growth. These malabsorption disorder equipment provider companies are called key companies of the market. They contribute to the largest share of the market profit.

The companies account for the market profits by adopting various malabsorption syndrome market trends such as joint ventures, product launches, company expansions, and procurements.

Key Players

Below are the key companies that malabsorption syndrome diagnosis & treatment equipment in the global market:

• Abbvie Inc.


• AstraZeneca PLC


• DSM


• Gilead Sciences


• Glenmark Pharmaceuticals


• Lupin Pharmaceuticals Inc.


• McNeil Nutritionals


• Perrigo


• Roche


• Vetbiochem India Private Limited


• Actelion Pharmaceuticals Ltd


• Bayer Healthcare AG


• Eli Lily and Company


• GlaxoSmithKline plc.


• KLAIRE LABORATORIES


• Mallinckrodt Pharmaceuticals


• National Enzyme Company


• Pfizer Inc.


• Sanofi

Recent Developments 

• Many of the key players of the market are adopting various initiatives such as product launches, advancements in equipment technology, and others. Moreover, they are investing a lot in the research and development of the market.

Report Overview 

This report delivers all the information about the global malabsorption syndrome market size in the forecast period. It also contains different sections of the market analysis to help obtain detailed information such as opportunities, challenges, drivers, Covid-19 analysis, regional analysis, competitive landscape, and others. Moreover, all the information is collected from verified primary and secondary sources to provide the expected market outlook.

Geographically

• Europe


• Asia-Pacific


• North America


• Middle East & Africa


• Rest of the world